



ASCO 2024 TIP SHEET: *Research findings from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami will be presented at ASCO 2024 – the American Society of Clinical Oncology’s annual meeting May 31–June 4 in Chicago. Below are links and titles for more than 60 oral presentations, posters and special sessions in which our researchers will be involved. For more information or to arrange interviews, please contact Sandy Van. Sandy.Van@miami.edu or call/text 808.206.4576. Thank you.*

Oral Presentations (10)

1. [Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell \(PBSC\) transplantation.](#)
Dr. Antonio Jimenez Jimenez is last author.
2. [Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab \(pem\) in patients \(pts\) with metastatic melanoma \(mMEL\) with disease progression on anti-PD-1 therapy.](#) Dr. Leonel Hernandez-Aya is a co-author.
3. [Preliminary safety and efficacy of oral azacitidine \(Oral-AZA\) in patients \(pts\) with low-/Intermediate \(Int\)-risk myelodysplastic syndromes \(MDS\): Phase 2 results from the ASTREON trial.](#) Dr. Mikkael A. Sekeres is a co-author.
4. [Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.](#) Dr. Georgios Pongas is a co-author.
5. [Outcomes of advanced/metastatic breast cancer \(aMBC\) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.](#) Dr. Carmen Calfa is first author.
6. [StrateGIST 1: A first-in-human \(FIH\), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors \(TKIs\).](#) Dr. Jonathan Trent is a co-author.
7. [Biomarker analyses in patients with advanced renal cell carcinoma \(aRCC\) from the phase 3 CLEAR trial.](#) Dr. Jaime Merchan is a co-author.
8. The More the Better? Quadruplets in Newly Diagnosed Multiple Myeloma
Dr. C. Ola Landgren is a discussant.
9. [Assessing gender disparities in oncology: Less talk, more action.](#)
Dr. Coral Olazagasti is first author. (RAPID ORAL)
10. [Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma \(HCRN MEL17-309\).](#)
Dr. Leonel Hernandez-Aya is a co-author. (RAPID ORAL)

Special Sessions (4)

1. [How Social Media Advances Research and Promotes Professional Development](#)
Dr. Gilberto Lopes is presenting. (EDUCATION SESSION)

2. [Going back home: Understanding the challenges of international medical graduates \(IMGs\) in oncology.](#) Dr. Coral Olazagasti is a co-author. (CLINICAL SCIENCE SYMPOSIUM)
3. [International medical graduates \(IMG\) representation at international oncology conference meetings.](#) Dr. Gilberto Lopes is a co-author. (CLINICAL SCIENCE SYMPOSIUM)

Posters (50)

1. [Biomarker development from functional precision medicine datasets via explainable machine learning.](#) Dr. Daria Salyakina is a co-author.
2. [Association of germline HSD3B1 \(c.1100\) genotype with tumoral and clinical outcomes in breast and endometrial cancers.](#) Dr. Nima Sharifi is a co-author.
3. [Variant of uncertain significance \(VUS\) genetic testing results and mastectomy choice in lumpectomy-eligible patients.](#) Dr. Osvaldo Nunez is first author. Dr. Susan Kesmodel is a co-author. Dr. Kristin Rojas is last author.
4. [SV-BR-1-GM after progression on ADC in patients with metastatic breast cancer.](#) Dr. Carmen Calfa is a co-author.
5. [Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 \(guadecitabine\) or ASTX727 \(decitabine/cedazuridine\) for advanced conventional chondrosarcoma \(cCS\).](#) Dr. Gina D'Amato is a co-author.
6. [Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib \(CGT9486\) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors \(GIST\).](#) Dr. Jonathan Trent is a co-author.
7. [Characterizing patterns of mTORC1 activation across sarcoma subtypes using single-sample gene set enrichment analysis \(ssGSEA\) and a national biomarker database.](#) Drs. Gina D'Amato and Jonathan Trent are co-authors.
8. [A signal-finding study of nivolumab and relatlimab in patients with advanced chordoma.](#) Dr. Nicholas Bernthal is last author.
9. [Sorafenib treatment duration in desmoid tumors.](#) Drs. Steven Bialick, Gina D'Amato, and Jonathan Trent are co-authors.
10. [Experience of young patients with cancer discussing cannabis with their providers.](#) Dr. Amrit Baral is first author. Drs. Bria-Necole Diggs, Ranya Marrakchi El Fellah, Nicolas Hernandez Ortega, and Frank Penedo are co-authors. Dr. Denise Vidot is last author.
11. [Clinical utility and accessibility of functional precision medicine for relapsed/refractory pediatric and adult cancers.](#) Dr. Cima Saghira is a co-author.
12. [Dissecting racial/ethnic disparities in non-small cell lung cancer staging at diagnosis: Intra-ethnic and geographic differences.](#) Dr. Qinran Liu is first author. Drs. Tulay Koru-Sengul and Gilberto Lopes are co-authors. Dr. Paulo Pinheiro is the last author.
13. [Phase 1 LITESPARK-001 study of belzutifan in advanced solid tumors: Results of the glioblastoma cohort.](#) Dr. Macarena de la Fuente is a co-author.
14. [Polyploid circulating stromal cells in blood to identify invasive solid tumors and to prognosticate for highly aggressive cancer subtypes.](#) Drs. Sandra Gaston and Sanoj Punnen are co-authors.

15. [A novel MRI-based tumor-targeting theragnostic agent: Magnetolectric nanoparticles in an in vivo murine KRAS/P53 pancreatic flank tumor model.](#) Dr. Mokene Malafa is last author.
16. [Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.](#) Dr. Macarena de la Fuente is a co-author.
17. [The genomic, transcriptomic, and immunologic landscape of TEM8 \(ANTXR1\) in small-cell lung cancer \(SCLC\).](#) Dr. Samuel Kareff is first author. Dr. Gilberto Lopes is a co-author. Dr. Aman Chauhan is last author.
18. [Nivolumab plus ipilimumab \(N+I\) in patients \(pts\) with solid tumors with high tumor mutational burden \(HTMB\): Results from the Targeted Agent and Profiling Utilization Registry \(TAPUR\) Study.](#) Dr. Peter Hosein is a co-author.
19. [Pertuzumab plus trastuzumab \(P+T\) in patients \(pts\) with solid tumors with ERBB2 or ERBB3 amplification \(amp\) or mutations \(mut\): Results from the Targeted Agent and Profiling Utilization Registry \(TAPUR\) study.](#) Dr. Carmen Calfa is a co-author.
20. [Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.](#) Dr. Agustin Pimentel is a co-author.
21. [A phase 1 study to evaluate the safety and preliminary efficacy of minnelide given alone or in combination with paclitaxel in advanced gastric cancer.](#) Dr. Vineet K. Gupta is a co-author.
22. [Association of BRCA1/2 pathogenic variants with primary tumor location and metastatic organotropism in pancreatic adenocarcinoma.](#) Dr. Ryan Hood is first author.
23. [Lenvatinib plus pembrolizumab \(L+P\) vs sunitinib \(S\) in advanced renal cell carcinoma \(aRCC\): Patterns of progression and subsequent therapy in the CLEAR trial.](#) Dr. Jaime Merchan is a co-author.
24. [Matched tissue and circulating tumor DNA \(ctDNA\) analysis in renal cell carcinoma \(RCC\): Results from a multimodal real-world database.](#) Dr. Chinmay Jani is a co-author.
25. [Belzutifan in patients with advanced clear cell renal cell carcinoma \(ccRCC\): Subgroup analysis of the phase 2 LITESPARK-013 study.](#) Dr. Jaime Merchan is a co-author.
26. [Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001.](#) Dr. Jaime Merchan is a co-author.
27. [Dynamic androgen receptor alterations \(ARa\) ctDNA profiles and clinical outcomes in metastatic prostate cancer \(mPC\).](#) Dr. Chinmay Jani is first author.
28. [Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer.](#) Dr. Michael Antoni is a co-author.
29. [Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma \(HNSCC\).](#) Dr. Francisco Civantos is a co-author.
30. [Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.](#) Dr. Justin Watts is a co-author.
31. [Mutation profiles and outcomes of patients with acute myeloid leukemia with autoimmune disease.](#) Dr. Mikkael A. Sekeres is a co-author.

32. [Efficacy of imetelstat on red blood cell \(RBC\)-transfusion independence \(TI\) in the absence of platelet transfusions or myeloid growth factors in IMerge.](#) Dr. Mikkael A. Sekeres is a co-author.
33. [Bromodomain and extra-terminal \(BET\) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis \(MF\) and other advanced myeloid neoplasms: A phase 1 study.](#) Dr. Justin Watts is first author.
34. [Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients \(pts\) with primary refractory or early relapsed large B-cell lymphoma \(LBCL\).](#) Dr. Izidore Lossos is a co-author.
35. [Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed \(TCE\) relapsed/refractory multiple myeloma \(RRMM\).](#) Dr. James E. Hoffman is a co-author.
36. [The genomic, transcriptomic, and immunological profile of patients with recurrent/refractory NSCLC.](#) Dr. Dan Morgenstern Kaplan is first author. Drs. Samuel Kareff, Coral Olazagasti and Gilberto Lopes are co-authors. Dr. Estelamari Rodriguez is last author.
37. [Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer \(NSCLC\).](#) Dr. Gilberto Lopes is a co-author.
38. [Young adults \(YA\) with non-small cell lung cancer \(NSCLC\): Snapshot of the oncogenic drivers and immune landscapes.](#) Drs. Coral Olazagasti and Estelamari Rodriguez are co-authors.
39. [The DIET study: A randomized controlled trial of a high fiber diet intervention \(HFDI\) in patients \(pts\) with melanoma receiving immune checkpoint blockade \(ICB\).](#) Dr. Ashley Holly (DESAI, MSOM) is a co-author.
40. [Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.](#) Dr. Lynn Feun is a co-author.
41. [Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate \(ISAC\) BDC-1001 \(trastuzumab imbotolimod\) +/- pertuzumab \(P\) in patients \(pts\) with HER2-positive metastatic breast cancer \(MBC\) previously treated with trastuzumab deruxtecan \(T-DXd\).](#) Dr. Carmen Calfa is a co-author.
42. [DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.](#) Dr. Jonathan Trent is a co-author.
43. [Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib \(CGT9486\) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors \(GIST\).](#) Dr. Jonathan Trent is last author.
44. [GUIAR: Promoting lung cancer screening in Hispanic head and neck cancer survivors.](#) Dr. Coral Olazagasti is first author. Drs. Tracy Crane, Estelamari Rodriguez, Frank Penedo and Erin Kobetz are co-authors. Dr. Gilberto Lopes is last author.
45. [A phase 1/2 study of the TBL1 inhibitor, tegavivint \(BC2059\), in patients \(pts\) with advanced hepatocellular carcinoma \(aHCC\) with \$\beta\$ -catenin activating mutations.](#) Dr. Lynn Feun is a co-author.
46. [REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy \(LRT\) with transarterial chemoembolization \(TACE\) or transarterial radioembolization \(TARE\), for the first-line treatment of intermediate-stage hepatocellular carcinoma \(HCC\) with beyond up-to-7 criteria.](#) Dr. Riccardo Lencioni is a co-author.

47. [A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.](#) Dr. Aman Chauhan is first author.
48. [A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors \(E-VIRTUE\).](#) Dr. Marijo Bilusic is a co-author.
49. [Phase 1b trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior therapies.](#) Dr. Mikkael A. Sekeres is a co-author.
50. [Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients \(pts\) with relapsed/refractory \(R/R\) large B-cell lymphoma \(LBCL\) after CD19-directed CAR T-cell therapy.](#) Dr. Jay Spiegel is a co-author.

Publication-Only

For a full list of publication-only abstracts, please email Sandy.Van@miami.edu.

###

MEDIA CONTACT:

Sandy Van

Sandy.Van@miami.edu

808.206.4576